![]() Hospitals with optimised patient pathways and efficiency. Healthcare professionals with access to advanced technology and techniques. Creo Medical in Boydton, VA Expand search. Creo Medical’s pioneering products are used worldwide, providing: Patients with improved treatment options, focused on enhancing quality of life. We will incorporate the fund-raise into our estimates following shareholder approval and completion of the process. Creo raises gross proceeds of approx £33.7m, in aggregate, through Placing, Subscription and Open Offer. Notably, we estimate these funds to be sufficient to take Creo to net profitability (H126 as per our projections). Creo plans to use these funds to support its commercialisation plans, ongoing R&D efforts, licensing and partnering opportunities as well as working capital requirements. Creo Medical is focused on the emerging field of surgical endoscopy. In addition, Creo has announced an open offer to shareholders to raise another £5.2m in funds via the conditional issue of c 26m ordinary shares. UK-based Creo Medical focuses on the development and commercialisation of minimally invasive electrosurgical devices. Luis Collantes, President of Albyn Medical, commented: I am very pleased to join forces with Creo Medical as we enter a new exciting growth phase for our business. Their integrated electrosurgery unit delivers. Creo Medicals key executives include Charles Spicer and 6 others. Creo Medical are dedicated to improving patient outcomes by bringing advanced energy to therapeutic endoscopy. The fund-raising, subject to shareholder approval (AGM expected on 8 March), was oversubscribed against the minimum target of £25m, indicating strong shareholder support. Creo Medicals Chairman is Charles Spicer. Creo Medical, founded in 2003, is a medical device company focused on the development and commercialization by bringing advanced energy to endoscopy. In a bid to strengthen its balance sheet and support development programmes, Creo has announced a £28.5m (£26.8m net proceeds) fund- raise through institutional investors by placing 142.5m new ordinary shares at 20p/share (a 28% discount to the 15 February closing price). Manufacturing United Kingdom 290 Employees.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |